Evidence map›Paper›PMID 41136831›Full record

ReviewAdvances in experimental medicine and biology2025

Development of Regulation and Policy for Cell Therapies in China.

Tao Na, Kehua Zhang, Zhaohui Wu, Xuelin Wu, Tingting Wu, Xiaoyan Han, Wen Zhang, Miao Xu, Shufang Meng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tao NaNational Institutes for Food and Drug Control, Beijing, China.
Kehua ZhangNational Institutes for Food and Drug Control, Beijing, China.
Zhaohui WuChina Medicinal Biotech Association, Beijing, China.
Xuelin WuNational Institutes for Food and Drug Control, Beijing, China.
Tingting WuNational Institutes for Food and Drug Control, Beijing, China.
Xiaoyan HanNational Institutes for Food and Drug Control, Beijing, China.
Wen ZhangChina Medicinal Biotech Association, Beijing, China.
Miao Xu *National Institutes for Food and Drug Control, Beijing, China.
Shufang Meng *National Institutes for Food and Drug Control, Beijing, China. mengsf@nifdc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapy products (CTPs) have become a highly promising area within the realm of regenerative medicine research in China. In recent years, there has been a notable increase in the demand for new drug applications related to these innovative products. However, the diverse range of sources, biological functions, product types, and technologies associated with CTPs present considerable regulatory challenges. This article delves into how regulatory authorities in China have been continuously refining their frameworks, enhancing quality evaluation abilities, and fostering open communication and collaboration with the industry to tackle these challenges. These ongoing regulatory efforts have played a crucial role in facilitating the healthy and rapid growth of the clinical translation of CTPs in China.

Indexed as

Cell- and Tissue-Based TherapyHealth PolicyRegenerative MedicineChinaHumansCell therapy productQuality evaluationRegulatory frameworkRegulatory pathway

Identifiers

PMID41136831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.